Evidence map›Paper›PMID 40400996›Full record

ReviewAmerican journal of clinical and experimental urology2025

Dual role of autophagy in bone metastasis: mechanistic insights and therapeutic targeting.

Xinyi Gu, Dejian Xiang, Haozhong Zhu, Xiaoqian He, Chenhui Yang, Rongjin Chen

Abstract readReview
In one paragraph

Review in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyi GuDepartment of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine) Chengdu 611130, Sichuan, China.
Dejian XiangThe First People's Hospital of Guangyuan Guangyuan 628000, Sichuan, China.
Haozhong ZhuDepartment of Bone and Joint Surgery, The Affiliated Hospital of Southwest Medical University Luzhou 646000, Sichuan, China.
Xiaoqian HeDepartment of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine) Chengdu 611130, Sichuan, China.
Chenhui YangDepartment of Orthopedics, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu, China.
Rongjin ChenDepartment of Orthopedics, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy, a cellular degradation mechanism, plays a dual role in the progression and therapy of bone metastases in cancers, including prostate cancer. This review delves into the intricate roles of autophagy in both tumor suppression and progression, with a focus on its impact on bone metastasis and osteosarcoma (OS). Initially, autophagy acts as a tumor suppressor by eliminating damaged organelles and proteins, thus preventing tumor initiation. However, as cancer progresses, autophagy supports cancer cell survival under stress conditions, such as nutrient deprivation and hypoxia, and contributes to drug resistance. Specifically, in bone metastasis from breast and prostate cancers, autophagy facilitates tumor cell migration, invasion, and survival. The review also highlights the therapeutic potential of targeting autophagy in cancer treatment, especially in overcoming drug resistance in osteosarcoma, where autophagy modulation could reduce chemoresistance. By understanding the dual roles of autophagy in cancer and bone metastasis, new therapeutic strategies can be developed to target this process, offering hope for improved treatment outcomes in cancers prone to bone metastasis, including prostate cancer.

Indexed as

Autophagybone neoplasmsdrug resistanceneoplasm metastasisosteosarcomaprostate cancer

Identifiers

PMID40400996
PMCPMC12089224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.